<DOC>
	<DOCNO>NCT02882984</DOCNO>
	<brief_summary>A multi-center phase III randomize control study evaluate efficacy Hypofractionated SRS ( HFSRS ) along EGFR-TKI patient brain metastasis non-small cell lung cancer ( NSCLC ) . Assuming HFSRS inferior EGFR-TKI concurrent whole brain radiotherapy ( WBRT ) , primary end point intracranial PFS ( iPFS ) , secondary outcome include overall survival ( OS ) , evaluation cognitive function , quality life ( QoL ) adverse event .</brief_summary>
	<brief_title>Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease ( Hybrid )</brief_title>
	<detailed_description>WBRT remain standard care NSCL patient . Long term survival WBRT may noticeable cognitive dysfunction . The EGFR TKI reasonable control intracranial disease , duration EGFR TKI control disease variable due tendency drug resistance . To maintain intracranial disease control improve cognitive function , investigator propose use hypofractionated SRS multiple brain metastasis large brain lesion alone TKI .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histological cytological confirmation nonsmall cell lung cancer ( NSCLC ) ; Diagnosis brain metastasis Gadoliniumenhanced MRI . More 3 site intracranial metastasis , long diameter intracranial lesion 4 cm . Positive EGFR mutation . Life expectancy ≥3months . Have one measurable encephalic lesion accord RECIST . Adequate hematological function : Absolute neutrophil count ( ANC ) ≥1.5 x 109/L , Platelet count ≥100 x 109/L . Adequate renal function : Serum creatinine ≤1.5 x ULN , ≥ 50 ml/min . Adequate liver function : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) Alanine Aminotransferase ( ALT ) Aspartate Aminotransferase ( AST ) &lt; 2.5 x ULN absence liver metastasis , &lt; 5 x ULN case liver metastasis . Female subject pregnant . All human subject able comply require protocol followup procedure , able receive oral medication . Written inform consent provide . Previous usage EGFRTKI antibody EGFR : gefitinib , erlotinib , herceptin , erbitux . CSF MRI finding consistent metastasis spinal cord , meninges meningeal . Allergic Icotinib . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome , inability take oral medication , active peptic ulcer disease . Pregnancy breastfeed woman . Participate antitumor clinical trial 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>